Clinical trials: Patients With Diabetes.
Diabetes Mellitus, Type 2
A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 12-week clinical study is to evaluate the effect of vildagliptin 50mg qd, 50mg bid or 100mg qd compared to placebo in…
- Trial name
- NCT00351832
- Testing
- Vildagliptin
- Where
- Japan
- Volunteers
- 236 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations
The primary objective of this exploratory meta-analysis is to evaluate the frequencies, incidence rates, and hazard ratios of lower-limb amputation (LLA) events (primary outcome) and of adverse events related to amputation…
- Trial name
- NCT04937816
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 16,746 people
- Sponsor
- Boehringer Ingelheim
Type2 Diabetes Mellitus
A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
The objectives of the study is to evaluate the efficacy, safety, and dose of DS-8500a compared with placebo in patients with type 2 diabetes mellitus.
- Trial name
- NCT02628392
- Testing
- DS-8500a, Sitagliptin
- Where
- Japan
- Volunteers
- 368 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Type 2 Diabetes
MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus
An exploratory study to evaluate the Effect of Improving Glycemic Variability of Anagliptin Compared with Sitagliptin in Patients with Type 2 Diabetes Mellitus
- Trial name
- ACACIA (NCT04810507)
- Testing
- Anagliptin BID Treatment
- Where
- South Korea
- Volunteers
- 89 people
- Sponsor
- JW Pharmaceutical
Type 2 Diabetes Mellitus
Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)
Primary: Effect on HbA1c over 48 weeks in insulin-treated patients with type 2 diabetes Secondary: Effect on glucose, total daily insulin dose, body weight, waist circumference, HDL-cholesterol, triglycerides - Safety…
- Trial name
- NCT00288236
- Testing
- Rimonabant (SR141716)
- Where
- 12 sites in United States, Argentina and 10 more
- Volunteers
- 368 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2, Chronic Pain
Observatory on Elderly Patients "Les S.AGES"
Primary objective shared by the 3 registries : Describe the different pharmacotherapeutic management in patients : DB (Diabetes): with type 2 diabetes, treated with oral and / or injectable antidiabetics CP (Chronic Pain): with…
- Conditions
- Diabetes Mellitus, Type 2, Chronic Pain, Atrial Fibrillation
- Trial name
- NCT01065909
- Where
- France
- Volunteers
- 3,491 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes and moderate renal impairment.This study will be conducted at…
- Trial name
- DERIVE (NCT02413398)
- Testing
- Dapagliflozin 10 mg
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 321 people
- Sponsor
- AstraZeneca
Type2 Diabetes
Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients…
- Trial name
- NCT04170998
- Testing
- Evogliptin 5mg, Dapagliflozin 10mg, Metformin ≥ 1000mg
- Where
- South Korea
- Volunteers
- 283 people
- Sponsor
- Dong-A ST Co., Ltd.
Type 2 Diabetes Mellitus
Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
Japanese male and female patients with Type 2 Diabetes and aged ≥ 20 years old, with inadequate glycemic control on insulin defined as Haemoglobin A1c ≥ 7.2% and < 11% will be enrolled into the wash-out phase or directly into the…
- Trial name
- NCT02157298
- Testing
- Dapagliflozin 5 mg
- Where
- 14 sites in Japan
- Volunteers
- 266 people
- Sponsor
- AstraZeneca
Type 2 Diabetes, Hyperlipidemia
Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
A 16 week open-label study with subjects receiving background metformin monotherapy. 150 subjects randomized 1:1:1 to receive 1 of the following: open-label colesevelam HCl, open label rosiglitazone, or open-label sitagliptin.
- Trial name
- NCT00484419
- Testing
- Colesevelam HCl, rosiglitazone maleate, sitagliptin phosphate
- Where
- 20 sites in United States
- Volunteers
- 169 people
- Sponsor
- Daiichi Sankyo
IgA Nephropathy, Focal Segmental Glomerulosclerosis
Atrasentan in Patients With Proteinuric Glomerular Diseases
The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
- Conditions
- IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
- Trial name
- AFFINITY (NCT04573920)
- Testing
- Atrasentan
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea…
- Trial name
- NCT00575588
- Testing
- Metformin, Sulphonylurea, Saxagliptin
- Where
- 94 sites in Finland, Germany and 9 more
- Volunteers
- 891 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)
Primary objective: AT.LANTUS main study* To determine the optimal treatment algorithm for insulin glargine based on the incidence of severe hypoglycaemia.(*Target Number of patients for the main study:2346) HALT Sub-study** To…
- Trial name
- AT-LANTUS (NCT00390728)
- Testing
- Insulin Glargine
- Volunteers
- 2,346 people
- Sponsor
- Sanofi
Type 2 Diabetes
A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes
Phase 3 study to examine treatment with ITCA 650 compared to glimepiride when added to metformin monotherapy in reducing HbA1c in patients with type 2 diabetes.
- Trial name
- NCT01455922
- Testing
- ITCA 650, glimepiride
- Where
- United States
- Sponsor
- Intarcia Therapeutics
Diabetes Mellitus, Type 2
Insulin Glargine in Type 2 Diabetes Mellitus
Primary objective: To evaluate in explorative manner the fasting blood glucose (FBG) coefficient of variability (CV)calculated on SMBG values (SMBG : Self-Monitoring of Blood Glucose).
- Trial name
- NCT00272077
- Testing
- Insuline glargine
- Sponsor
- Sanofi
Type 2 Diabetes
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)
To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (both administered in combination with other anti-diabetic drugs) based on the change in HbA1c from baseline to 24 weeks
- Trial name
- INSTRIDE 2 (NCT02227875)
- Testing
- Mylan's insulin glargine, Lantus®
- Where
- 120 sites in United States, Jordan and 4 more
- Volunteers
- 560 people
- Sponsor
- Mylan Inc.
Pharmacological Action
Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients
Sitagliptin, through its effects on sensitizing alpha-cell sensitivity to glucose, can initiate counter-regulatory glucagon responses at higher glycemic thresholds, thus reducing the number of clinically apparent hypoglycemic…
- Trial name
- NCT03359590
- Testing
- Sitagliptin 100 mg
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Type 2 Diabetes
Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes
This extension study is designed to evaluate the long-term safety and tolerability of colesevelam hydrochloride (WelChol®) in patients with type 2 diabetes.
- Trial name
- NCT00151762
- Testing
- Colesevelam hydrochloride
- Where
- 64 sites in United States, Mexico and 1 more
- Volunteers
- 780 people
- Sponsor
- Daiichi Sankyo
Diabetes Mellitus Type 2
A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin
This single-center, randomized, double-blind, placebo-controlled study will evaluate the effect of aleglitazar on insulin sensitivity in patients with type 2 diabetes mellitus who are inadequately controlled on metformin…
- Trial name
- NCT01729403
- Testing
- aleglitazar, metformin
- Where
- Germany
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Infection
Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients
The use of the Percutaneous Isolated Limb Procedure (PILP) which enables the use of existing antibiotic therapies in a more targeted and concentrated fashion in patients with diabetes who have a significant lower limb infection…
- Trial name
- NCT02158442
- Testing
- Percutaneous Isolated Limb Perfusion (PILP) delivery, Timentin
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Osprey Medical, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.